MPH Health Care AG
XETRA:93M1
MPH Health Care AG
XETRA:93M1
Price:
26.8 EUR
4.69%
Updated:
May 16, 2024
Section:
Relative Value
The Relative Value of one
93M1
stock under the Base Case scenario is
0.2
EUR.
Compared to the current market price of 26.8 EUR,
MPH Health Care AG
is
Overvalued by 99%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
93M1
Relative Value
Base Case
0.2
EUR
Overvaluation 99%
Valuation Multiples
Multiples Across Competitors
93M1 Competitors Multiples
MPH Health Care AG Competitors
MPH Health Care AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
|
MPH Health Care AG
XETRA:93M1
|
114.7m EUR | 3 357 | 2.3 | -121.2 | -118.6 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
748B USD | 20.8 | 121.9 | 59.6 | 67.9 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 16.7 | 45.6 | 34.1 | 37.4 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
367.4B USD | 4.3 | 9.5 | 11.8 | 15.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
333.6B USD | 5.4 | 144.7 | 36 | 58.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
188.8B GBP | 5 | 37.8 | 174.6 | 278.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
187.2B CHF | 3.2 | 16.3 | 9.2 | 10.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
181.6B CHF | 3.4 | 11.5 | 8.7 | 12.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
162.7B USD | 3 | -526.6 | 13 | 20.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
